During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm. Novo […]
Copenhagen, Denmark, November 14, 2024 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of Directors. Gerd Zettlmeissl, the previous Chair, who was instrumental in the transition of MinervaX from a […]
2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year. M&A & deals Synaffix continued to build momentum – Lonza acquired the […]
New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company’s efforts to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a […]
Over 30 years ago, the International Day of Action for Women’s Health was established by women’s rights activists to speak out and raise awareness of reproductive, sexual and maternal health issues faced by women globally. Today, the awareness day is still observed and aims to strive towards a holistic, women-centric and rights-based approach to […]
